Sitryx announces partner Lilly exercises option to SIT-011 for chronic autoimmune and inflammatory diseases Lilly exercises option to an exclusive worldwide license to develop and commercialize SIT-011, a Phase 1 ready immunometabolism-targeting therapy for chronic autoimmune and inflammatory...

Sitryx further strengthens leadership team with the appointment of Iain Kilty, Ph.D., as Chief Scientific Officer Sitryx further strengthens leadership team with the appointment of Iain Kilty, Ph.D., as Chief Scientific Officer Oxford, UK – 15 April 2021 – Sitryx (“the Company”), a biopharmaceutical company...

Sitryx appoints Pierre Legault as Chairman of its Board of Directors Sitryx appoints Pierre Legault as Chairman of its Board of Directors Oxford, UK – 24 March 2021 - Sitryx, a biopharmaceutical company focused on regulating cell metabolism to develop...